SGLT2i use linked to lower risk for neurodegenerative disease in T2DM
By
HealthDay News
Sep 18, 2024
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.
Vision impairment contributes to dementia risk
By
Haymarket Media
Sep 11, 2024
Population-level dementia-attributable fractions from at least one visual impairment were highest among subpopulations of participants aged 71 to 79 years, female individuals and non-Hispanic white individuals,...
Diabetes, prediabetes tied to accelerated brain aging
By
Haymarket Media
Sep 10, 2024
The association was strongest among men and people with poor cardiometabolic health.
Dementia diagnoses up in individuals with acute kidney injury
By
Haymarket Media
Sep 05, 2024
Developing AKI was associated with a significantly increased rate of subsequent dementia; the pattern was consistent across dementia types.
SGLT-2 inhibitors may cut dementia risk in patients with diabetes
By
Haymarket Media
Sep 03, 2024
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
Cholinesterase inhibitors beneficial for dementia with Lewy bodies
By
Haymarket Media
Aug 28, 2024
The use of cholinesterase inhibitors significantly slowed cognitive decline at follow-ups compared with memantine and nonuse.
Risk for dementia similar with SGLT2 inhibitors, dulaglutide in T2DM
Aug 26, 2024
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.
Psychological well-being declines years before diagnosis of MCI
Aug 20, 2024
The findings were seen specifically for the components of purpose in life and personal growth.
Regional variation seen in Alzheimer’s and related dementia diagnosis
Aug 19, 2024
The ADRD-specific diagnosis intensity varies most for Black, Hispanic and youngest subgroups.
Risk for Alzheimer’s dementia lower with treated versus untreated HTN
Aug 14, 2024
The all-cause dementia risk was greater for those with treated and untreated hypertension compared with healthy controls.